2-ethynyl-5-(1-hydroxy-1-methylethyl)pyridine | 1055073-71-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-ethynyl-5-(1-hydroxy-1-methylethyl)pyridine
• 英文别名: 2-(6-Ethynylpyridin-3-yl)propan-2-ol
• CAS: 1055073-71-6
• 化学式: C₁₀H₁₁NO
• 分子量: 161.203
• InChiKey: VCWFNNTVULGSQZ-UHFFFAOYSA-N

物化性质

• 沸点：
  278.0±30.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  33.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-ethynyl-5-(1-hydroxy-1-methylethyl)pyridine 、 ethyl (2-iodo-5-(1-methyl-5-oxopyrrolidin-2-yl)-4-((6-(methylsulfonyl)pyridin-3-yl)oxy)phenyl)carbamate 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus

  摘要：

  Glucokinase (GK, hexokinase IV) is a unique hexokinase that plays a central role in mammalian glucose homeostasis. Glucose phosphorylation by GK in the pancreatic beta-cell is the rate-limiting step that controls glucose-stimulated insulin secretion. Similarly, GK-mediated glucose phosphorylation in hepatocytes plays a major role in increasing hepatic glucose uptake and metabolism and possibly lowering hepatic glucose output. Small molecule GK activators (GKAs) have been identified that increase enzyme activity by binding to an allosteric site. GKAs offer a novel approach for the treatment of Type 2 Diabetes Mellitus (T2DM) and as such have garnered much attention. We now report the design, synthesis, and biological evaluation of a novel series of 2,5,6-trisubstituted indole derivatives that act as highly potent GKAs. Among them, Compound 1 was found to possess high in vitro potency, excellent physicochemical properties, and good pharmacokinetic profile in rodents. Oral administration of Compound 1 at doses as low as 0.03 mg/kg led to robust blood glucose lowering efficacy in 3 week high fat diet-fed mice. (C) 2016 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2016.10.085
• 作为产物：
  描述：

  5-(1-hydroxy-1-methylethyl)-2-[(trimethylsilyl)ethynyl]pyridine 生成 2-ethynyl-5-(1-hydroxy-1-methylethyl)pyridine
  参考文献：
  名称：

  Alkyne-aryl phosphodiesterase-4 inhibitors

  摘要：

  由公式(I)表示的化合物： 1 或其药用可接受的盐，是磷酸二酯酶4抑制剂，用于治疗哮喘和炎症。

  公开号：

  US20030114478A1

文献信息

• [EN] ACETYL PYRROLIDINYL INDOLE DERIVATIVE<br/>[FR] DÉRIVÉ ACÉTYLE PYRROLIDINYLE INDOLE
  申请人：BANYU PHARMA CO LTD

  公开号：WO2010018800A1

  公开（公告）日：2010-02-18

  The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a lower alkylsulfonyl group; R2 represents a hydrogen atom; R20 represents, e.g., a hydrogen atom; m represents an integer of from 1 to 3; and n represents zero or 1, or relates to a pharmaceutically acceptable salts thereof.

  本发明涉及一种化合物，用于治疗和/或预防糖尿病、糖尿病并发症或肥胖症，因为这些化合物具有激活葡萄糖激酶的作用，并且以式（I）呈现：其中R1代表较低的烷基磺酰基；R2代表氢原子；R20代表例如氢原子；m表示1至3之间的整数；n表示零或1，或者与其药学上可接受的盐有关。
• Use of phosphodiesterase-4 inhibitors as enhancers of cognition
  申请人：Dube Daniel

  公开号：US20060040981A1

  公开（公告）日：2006-02-23

  The present invention is directed to a method of enhancing cognition in a healthy subject comprising administering a safe cognition enhancing amount of a phosphodiesterase-4 inhibitor. In particular, this invention is directed to a method of enhancing memory, learning, retention, recall, awareness and judgement in health subjects comprising administering a safe and effective amount of a phosphodiesterase-4 inhibitor.

  本发明涉及一种增强健康受试者认知能力的方法，包括给予安全的磷酸二酯酶-4抑制剂增强认知能力的剂量。特别地，本发明涉及一种增强健康受试者记忆、学习、保留、回忆、意识和判断力的方法，包括给予安全有效的磷酸二酯酶-4抑制剂的剂量。
• Use of pde4 inhibitors as adjunct therapy for psychiatric disorders
  申请人：Scolnick M. Edward

  公开号：US20060069115A1

  公开（公告）日：2006-03-30

  The use of a PDE4 inhibitor in conjunction with psychotherapy provides enhanced therapeutic results in the treatment of psychiatric disorders including, for example, specific phobias, panic disorders, anxiety disorders including posttraumatic stress disorders, and obsessive-compulsive disorder.

  在治疗精神障碍，例如特定恐惧症、惊恐障碍、包括创伤后应激障碍和强迫症的焦虑障碍中，与心理治疗同时使用PDE4抑制剂可以提供增强的治疗效果。
• Alkyne-aryl-naphthyridin-4(1h)-one derivatives as type IV phosphodiesterase inhibitor
  申请人：Merck Frosst Canada Limited

  公开号：EP2305677A1

  公开（公告）日：2011-04-06

  Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterase 4 inhibitors useful in the treatment of asthma and inflammation.

  式 (I) 所代表的化合物： 或其药学上可接受的盐为磷酸二酯酶 4 抑制剂，可用于治疗哮喘和炎症。
• ALKYNE-ARYL-NAPHTHYRIDIN-4(1H)-0NE DERIVATIVES AS TYPE IV PHOSPHODIESTERASE INHIBITOR
  申请人：Merck Frosst Canada Ltd.

  公开号：EP1436290B1

  公开（公告）日：2013-09-18